Brief research report: in-depth immunophenotyping reveals stability of CD19 CAR T-cells over time

Variability or stability might have an impact on treatment success and toxicity of CD19 CAR T-cells. We conducted a prospective observational study of 12 patients treated with Tisagenlecleucel for CD19 B-cell malignancies. Using a 31-color spectral flow cytometry panel, we analyzed differentiation s...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in immunology 2024, Vol.15, p.1298598-1298598
Main Authors: Odak, Ivan, Bayir, Lâle M, Riemann, Lennart, Sikora, Ruth, Schneider, Jessica, Xiao, Yankai, Möhn, Nora, Skripuletz, Thomas, Beutel, Gernot, Eder, Matthias, Ganser, Arnold, Förster, Reinhold, Schultze-Florey, Christian R, Koenecke, Christian
Format: Article
Language:English
Subjects:
Adaptor Proteins, Signal Transducing
ALL acute lymphoblastic leukemia
Antigens, CD19
CAR T-cell
DLBCL diffuse large B-cell lymphoma
Humans
Immunology
Immunophenotyping
Research Report
spectral flow cytometry
T-Lymphocytes
tisagenlecleucel tisa-cel
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Variability or stability might have an impact on treatment success and toxicity of CD19 CAR T-cells. We conducted a prospective observational study of 12 patients treated with Tisagenlecleucel for CD19 B-cell malignancies. Using a 31-color spectral flow cytometry panel, we analyzed differentiation stages and exhaustion markers of CAR T-cell subsets prior to CAR T-cell infusion and longitudinally during 6 months of follow-up. The majority of activation markers on CAR T-cells showed stable expression patterns over time and were not associated with response to therapy or toxicity. Unsupervised cluster analysis revealed an immune signature of CAR T-cell products associated with the development of immune cell-associated neurotoxicity syndrome. Warranting validation in an independent patient cohort, in-depth phenotyping of CAR T-cell products as well as longitudinal monitoring post cell transfer might become a valuable tool to increase efficacy and safety of CAR T-cell therapy.
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2024.1298598